Werner Goebel

Title: Werner Goebel: Innovator in Bacterial Therapeutics

Introduction

Werner Goebel is a notable inventor based in Munich, Germany. He has made significant contributions to the field of biotechnology, particularly in the development of non-pathogenic bacteria for therapeutic applications. With a total of 2 patents, his work focuses on innovative solutions for medical challenges.

Latest Patents

Goebel's latest patents include groundbreaking inventions. The first patent describes non-pathogenic and/or attenuated bacteria capable of inducing apoptosis in macrophages. This invention relates to a bacterium that can effectively trigger programmed cell death in immune cells, potentially leading to new treatments for various diseases. The second patent involves microorganisms as carriers of nucleotide sequences coding for antigens and protein toxins. This invention outlines a Pseudomonas bacterium that incorporates multiple polynucleotides, enabling it to express and secrete proteins that can elicit a targeted immune response against tumor cells.

Career Highlights

Throughout his career, Werner Goebel has worked with prominent companies in the biotechnology sector. He has been associated with Zentaris GmbH and Aeterna Zentaris GmbH, where he contributed to research and development efforts aimed at advancing therapeutic technologies.

Collaborations

Goebel has collaborated with esteemed colleagues in his field, including Joachim Fensterle and Ulf R Rapp. These partnerships have fostered innovation and have been instrumental in the development of his patented technologies.

Conclusion

Werner Goebel's contributions to the field of biotechnology through his patents and collaborations highlight his role as a key innovator. His work continues to pave the way for advancements in medical therapies using bacterial systems.